Abstract:BACKGROUND:Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with high tumour PD-L1 expression remain resistant to immune checkpoint inhibitors. To understand the underlying resistance mechanisms, characterization of the immunosuppressive tumour microenvironment and identification of biomarkers to predict resistance in patients are urgently needed.METHODS:Our study retrospectively analysed RNA sequencing data of 624 LUSC samples. We analysed gene expression patterns from tumour microenvironment by unsupervised clustering. We correlated the expression patterns with a set of T cell exhaustion signatures, immunosuppressive cells, clinical characteristics, and immunotherapeutic responses. Internal and external testing datasets were used to validate the presence of exhausted immune status.RESULTS:Approximately 28 to 36% of LUSC patients were found to exhibit significant enrichments of T cell exhaustion signatures, high fraction of immunosuppressive cells (M2 macrophage and CD4 Treg), co-upregulation of 9 inhibitory checkpoints (CTLA4, PDCD1, LAG3, BTLA, TIGIT, HAVCR2, IDO1, SIGLEC7, and VISTA), and enhanced expression of anti-inflammatory cytokines (e.g. TGFβ and CCL18). We defined this immunosuppressive group of patients as exhausted immune class (EIC). Although EIC showed a high density of tumour-infiltrating lymphocytes, these were associated with poor prognosis. EIC had relatively elevated PD-L1 expression, but showed potential resistance to ICB therapy. The signature of 167 genes for EIC prediction was significantly enriched in melanoma patients with ICB therapy resistance. EIC was characterized by a lower chromosomal alteration burden and a unique methylation pattern. We developed a web application ( http://lilab2.sysu.edu.cn/tex & http://liwzlab.cn/tex ) for researchers to further investigate potential association of ICB resistance based on our multi-omics analysis data.CONCLUSIONS:We introduced a novel LUSC immunosuppressive class which expressed high PD-L1 but showed potential resistance to ICB therapy. This comprehensive characterization of immunosuppressive tumour microenvironment in LUSC provided new insights for further exploration of resistance mechanisms and optimization of immunotherapy strategies.

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

1304P Interleukin-6 (IL-6) As a Potential Predictive Marker and a Desensitizer for Immunotherapy Response in Non-Small Cell Lung Cancer

Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer

1463P IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer

Identification of Immune-Related Gene Signature for Non-Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors

Profiling of Immune Features to Predict Immunotherapy Efficacy

Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer

The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer

Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

P33.07 Peripheral CD4+ T Cell Signatures in Predicting Response to Anti-PD-1 Monotherapy for Chinese Advanced Non-Small Cell Lung Cancer Patients

Plasma D-dimer and interleukin-6 are associated with treatment response and progression-free survival in advanced NSCLC patients on anti-PD-1 therapy

Plasma Cytokines Interleukin-18 and C-X-C Motif Chemokine Ligand 10 Are Indicative of the Anti-Programmed Cell Death Protein-1 Treatment Response in Lung Cancer Patients

Identification of a Cytokine-Dominated Immunosuppressive Class in Squamous Cell Lung Carcinoma with Implications for Immunotherapy Resistance.

Immune signatures of patients with advanced non-small-cell lung cancer for efficacy prediction after immunotherapy

Elevated IL-6/IL-1Ra Ratio As a Prognostic Biomarker of Poor Chemotherapy Efficacy in Chinese Patients with Metastatic NSCLC, Validated in a Caucasian Patient Cohort

EP08.01-097 Landscape and Dynamic Changes of Peripheral Immune Cells in Non-small Cell Lung Cancer Patients with First-line Immunotherapy

A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer